Search Results - "CONFAVREUX, E"

Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene by MEUNIER, P. J, VIGNOT, E, GARNERO, P, CONFAVREUX, E, PARIS, E, LIU-LEAGE, S, SARKAR, S, LIU, T, WONG, M, DRAPER, M. W

“…Raloxifene, a selective estrogen receptor modulator (SERM), has been shown to improved bone mineral density (BMD) and serum lipid profiles in healthy…”
Get full text

Prevention of early postmenopausal bone loss with cyclical etidronate therapy (A double-blind, placebo-controlled study and 1-year follow-up) by MEUNIER, P. J, CONFAVREUX, E, TUPINON, I, HARDOUIN, C, DELMAS, P. D, BALENA, R

“…The objective of the study was to evaluate the effects of cyclical therapy with etidronate and calcium on spinal and femoral bone loss in the early post…”
Get full text

A combination of low doses of 17β-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women by DELMAS, P. D, CONFAVREUX, E, GARNERO, P, FARDELLONE, P, DE VERNEJOUL, M.-C, CORMIER, C, ARCE, J.-C

“…The effects of 17 beta-estradiol (E2) 1 mg combined with low doses of norethisterone acetate (NETA) on postmenopausal bone loss and turnover were investigated…”
Get full text

Maintien de l'efficacité et de la tolérance de l'ibandronate oral mensuel (150 mg) : extension de l'étude MOBILE by Delmas, P.-D., Ravoux, A.-C., Confavreux, E., Duvert, F.

Get full text

A Combination of Low Doses of 17[beta]-Estradiol and Norethisterone Acetate Prevents Bone Loss and Normalizes Bone Turnover in Postmenopausal Women by Delmas, P D, Confavreux, E, Garnero, P, Fardellone, P, de Vernejoul, M-c, Cormier, C, Arce, J-c

“…The effects of 17β-estradiol (E^sub 2^) 1 mg combined with low doses of norethisterone acetate (NETA) on postmenopausal bone loss and turnover were…”
Get full text

Intermittent risedronate prevents bone loss in women with artificial menopause induced by chemotherapy of breast cancer by Delmas, P.D., Hardouin, C., Confavreux, E., Hardy, P., Bremond, A.

Get full text

Prevention of Early Postmenopausal Bone Loss with Cyclical Etidronate Therapy (A Double-Blind, Placebo-Controlled Study and 1-Year Follow-Up) by Meunier, P. J., Confavreux, E., Tupinon, I., Hardouin, C., Delmas, P. D., Balena, R.

“…Abstract The objective of the study was to evaluate the effects of cyclical therapy with etidronate and calcium on spinal and femoral bone loss in the early…”
Get full text

Prevention of Early Postmenopausal Bone Loss with Cyclical Etidronate Therapy (A Double-Blind, Placebo-Controlled Study and 1-Year Follow-Up)1 by Meunier, P. J, Confavreux, E, Tupinon, I, Hardouin, C, Delmas, P. D, Balena, R

“…The objective of the study was to evaluate the effects of cyclical therapy with etidronate and calcium on spinal and femoral bone loss in the early post…”
Get full text

Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group by Meunier, P J, Vignot, E, Garnero, P, Confavreux, E, Paris, E, Liu-Leage, S, Sarkar, S, Liu, T, Wong, M, Draper, M W

“…Raloxifene, a selective estrogen receptor modulator (SERM), has been shown to improved bone mineral density (BMD) and serum lipid profiles in healthy…”
Get full text